Compare TBPH & CRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | CRCT |
|---|---|---|
| Founded | 2013 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Wholesale Distributors |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.7M | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | TBPH | CRCT |
|---|---|---|
| Price | $18.67 | $4.95 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 5 | 3 |
| Target Price | ★ $27.80 | $4.18 |
| AVG Volume (30 Days) | ★ 528.0K | 448.8K |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 19.27% |
| EPS Growth | N/A | ★ 27.98 |
| EPS | ★ 0.58 | 0.37 |
| Revenue | $80,327,000.00 | ★ $714,492,000.00 |
| Revenue This Year | $70.78 | $1.06 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.28 | ★ $13.34 |
| Revenue Growth | ★ 27.12 | N/A |
| 52 Week Low | $7.90 | $3.94 |
| 52 Week High | $20.33 | $7.33 |
| Indicator | TBPH | CRCT |
|---|---|---|
| Relative Strength Index (RSI) | 57.92 | 44.63 |
| Support Level | $17.25 | $4.94 |
| Resistance Level | $19.13 | $5.35 |
| Average True Range (ATR) | 0.65 | 0.14 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 78.72 | 8.79 |
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Cricut Inc designs and builds a creativity platform that enables users to turn ideas into professional-looking handmade goods. With its connected machines, design apps and accessories, and materials, the users create everything from personalized birthday cards, mugs and T-shirts to large-scale interior decorations. It has two segments including the Platform segment which derives revenue from monthly and annual subscription fees, purchases of digital content, and a minimal amount of the revenue allocated to unspecified future upgrades and enhancements related to the essential software and access to the Company's cloud-based services and Products segment which derives revenue from the sale of its connected machine hardware, and sale of craft, DIY, home decor products and extensions.